A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Vibegron, a novel, potent β3 agonist, has been approved for clinical use in overactive bladder (OAB) treatment in Japan and the Unites States. We performed a bridging study to investigate the efficacy and safety of a daily 50-mg vibegron (code name JLP-2002) dose in Korean patients with OAB. Methods: A multicenter, randomized, double-blind, placebo-controlled study was conducted from September 2020 to August 2021. Adult patients with OAB with a symptom duration of more than 6 months entered a 2-week placebo run-in phase. Eligibility was assessed at the end of this phase and selected patients entered a double-blind treatment phase after 1:1 randomization to either the placebo or vibegron (50 mg) group. The study drug was administered once daily for 12 weeks and follow-up visits were scheduled at weeks 4, 8, and 12. The primary endpoint was the change in mean daily micturition at the end of treatment. The secondary endpoints included changes in OAB symptoms (daily micturition, nocturia, urgency, urgency incontinence, and incontinence episodes, and mean voided volume per micturition) and safety. A constrained longitudinal data model was used for statistical analysis. Results: Patients who took daily vibegron had significant improvements over the placebo group in both primary and secondary endpoints, except for daily nocturia episodes. The proportions of patients with normalized micturition and resolution of urgency incontinence and incontinence episodes were significantly higher in vibegron group than in the placebo. Vibegron also improved the patients’ quality of life with higher satisfaction rates. The incidence of adverse events in the vibegron and placebo groups was similar with no serious, unexpected adverse drug reactions. No abnormality in electrocardiographs was observed as well as no significant increase in postvoid residual volume. Conclusions: Once daily vibegron (50 mg) for 12 weeks was effective, safe, and well-tolerated in Korean patients with OAB.
Abstract
Purpose: Vibegron, a novel, potent β3 agonist, has been approved for clinical use in overactive bladder (OAB) treatment in Japan and the Unites States. We performed a bridging study to investigate the efficacy and safety of a daily 50-mg vibegron (code name JLP-2002) dose in Korean patients with OAB. Methods: A multicenter, randomized, double-blind, placebo-controlled study was conducted from September 2020 to August 2021. Adult patients with OAB with a symptom duration of more than 6 months entered a 2-week placebo run-in phase. Eligibility was assessed at the end of this phase and selected patients entered a double-blind treatment phase after 1:1 randomization to either the placebo or vibegron (50 mg) group. The study drug was administered once daily for 12 weeks and follow-up visits were scheduled at weeks 4, 8, and 12. The primary endpoint was the change in mean daily micturition at the end of treatment. The secondary endpoints included changes in OAB symptoms (daily micturition, nocturia, urgency, urgency incontinence, and incontinence episodes, and mean voided volume per micturition) and safety. A constrained longitudinal data model was used for statistical analysis. Results: Patients who took daily vibegron had significant improvements over the placebo group in both primary and secondary endpoints, except for daily nocturia episodes. The proportions of patients with normalized micturition and resolution of urgency incontinence and incontinence episodes were significantly higher in vibegron group than in the placebo. Vibegron also improved the patients’ quality of life with higher satisfaction rates. The incidence of adverse events in the vibegron and placebo groups was similar with no serious, unexpected adverse drug reactions. No abnormality in electrocardiographs was observed as well as no significant increase in postvoid residual volume. Conclusions: Once daily vibegron (50 mg) for 12 weeks was effective, safe, and well-tolerated in Korean patients with OAB.
참고문헌 (26)
- Haylen BT, "An International Urogynecological Association(IUGA)", International Continence Society(ICS)joint report on the terminology for female pelvic floor dysfunction, 2010, pp.29, 4~20
- 김태헌, "Persistence and compliance with medication management in the treatment of overactive bladder", Investigative and Clinical Urology, 57(2), pp.84~93 (2016), 대한비뇨의학회[DOI]
- Gormley EA, "Diagnosis and treatment of overactive bladder (non-neurogenic)in adults: AUA", SUFU guideline amendment, 2015, pp.193, 1572~1580
- Kelleher C, "Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder : a systematic review and network meta-analysis", Eur Urol, 74, pp.324~333 (2018)
- Wagg A, "Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder", Int J Clin Pract, 64, pp.1279~1286 (2010)
- Carlson KV, "Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome : findings from the PERSPECTIVE registry study", Low Urin Tract Symptoms, 13, pp.425~434 (2021)
- Lee KS, "Mirabegron has longer treatment persistence than antimuscarinics : realworld data from a Korean national cohort database", Neurourol Urodyn, 40, pp.1972~1980 (2021)
- Keam SJ, "Vibegron : first global approval", Drugs, 78, pp.1835~1839 (2018)
- "Vibegron (Gemtesa) for overactive bladder", Med Lett Drugs Ther, 63 (2021)
- Yoshida M, "Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study", Eur Urol, 73, pp.783~790 (2018)
- Staskin D, "International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR", J Urol, 204, pp.316~324 (2020)
- Staskin D, "Once-daily vibegron 75 mg for overactive bladder : long-term safety and efficacy from a double-blind extension study of the international phase 3 trial(EMPOWUR)", J Urol, 205, pp.1421~1429 (2021)
- Yoshida M, "Long-term safety and efficacy of the novel beta3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder : a phase III prospective study", Int J Urol, 25, pp.668~675 (2018)
- Tachikawa K, "Efficacy of vibegron in patients with overactive bladder: multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01", Low Urin Tract Symptoms, 14, pp.109~116 (2022)
- Frankel J, "Vibegron improves quality-of-life measures in patients with overactive bladder : patient-reported outcomes from the EMPOWUR study", Int J Clin Pract, 75, pp.e13937~ (2021)
- Yoshida M, "Cardiovascular safety of vibegron, a new beta3-adrenoceptor agonist, in older patients with overactive bladder: posthoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study", Neurourol Urodyn, 40, pp.1651~1660 (2021)
- Mitcheson HD, "Vibegron (RVT-901", MK-4618, Eur Urol, pp.2019, 75[DOI]
- Su S, "Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder", Medicine(Baltimore), 100, pp.e23171~ (2021)
- Brucker BM, "Selectivity and maximum response of vibegron and mirabegron for beta(3)-adrenergic receptors", Curr Ther Res Clin Exp, 96, pp.100674~ (2022)
- Mukai S, "The 1-year continuation rate and discontinuation factors of vibegron and mirabegron : a retrospective comparative study in a rehabilitation hospital in Japan", Low Urin Tract Symptoms, 13, pp.448~455 (2021)
- Kennelly MJ, "Efficacy of vibegron and mirabegron for overactive bladder : a systematic literature review and indirect treatment comparison", Adv Ther, 38, pp.5452~5464 (2021)
- Kennelly M, "Longterm efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder : a systematic review and network meta-analysis", Drugs Context, 11, pp.2022-4-2~ (2022)
- He W, "Efficacy and safety of vibegron compared with mirabegron for overactive bladder : a systematic review and network meta-analysis", Low Urin Tract Symptoms, 15, pp.80~88 (2023)
- Chen JV, "Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States", J Med Econ, 25, pp.1092~1100 (2022)
- Kinjo M, "Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder : a randomized controlled study", Urology, 175, pp.67~73 (2023)
- Edmondson SD, "Discovery of vibegron : a potent and selective beta3adrenergic receptor agonist for the treatment of overactive bladder", J Med Chem, 59, pp.609~623 (2016)